Efficacy of Transfer Factor to Prevent Upper Respiratory Tract Infections in Healthy Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

49 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2010-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goals of our study are to critically evaluate if a healthy population supplemented with Transfer factor experiences fewer incidences of colds and flu, or experience shorter duration of illness compared to an identical population taking placebo. In this study we will give either Transfer factor or a placebo to two groups of healthy adult men and women for a period of 7 weeks in a double-blind experimental design. The frequency and duration of colds and flu-like symptoms will be recorded during the course of the study. Saliva samples will be collected weekly and assessed for salivary IgA secretion rate. Data from this study will establish the efficacy of Transfer Factor to support a healthy immune system.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

REDucing Influenza Among University Students, University of California at Berkeley

NCT00448773

Influenza-like Illness Influenza

COMPLETED PHASE4

Safety and Efficacy of Oral Colostrum Derived Anti Influenza Antibodies in Healthy Volunteers

NCT01026350

Influenza

UNKNOWN PHASE1

Influenza Immunity in Children

NCT02559505

Influenza

COMPLETED NA

Evaluating Immune Response to Seasonal FluMist in Healthy Adults

NCT01673425

Influenza

TERMINATED NA

From Innovation to Solutions: Childhood Influenza Vaccination Planning

NCT01664793

Influenza

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Upper Respiratory Tract Infections Due to Influenza or Rhinovirus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Transfer Factor

Transfer factor supplement; 2 capsules per day

Group Type ACTIVE_COMPARATOR

transfer factor

Intervention Type DIETARY_SUPPLEMENT

capsules, 2 per day by mouth for 7 weeks.

Sugar pill

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

cornstarch, 2 capsules per day by mouth.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

transfer factor

capsules, 2 per day by mouth for 7 weeks.

Intervention Type DIETARY_SUPPLEMENT

Placebo

cornstarch, 2 capsules per day by mouth.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females (18 - 40) who are in good health

Exclusion Criteria

* Subjects who are allergic to eggs (on which the supplement is based). If a volunteer is not sure if they are allergic to eggs or milk. Those who are currently smoking, have cardiovascular disease, cancer, diabetes, liver disease, renal insufficiency, any chronic disease that might interfere with study participation, BMI above 40 kg/m2, consumption of \>12 alcoholic drinks weekly, or unwillingness to stop current supplement intake. Women who are pregnant or lactating will also be excluded from the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes